Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Industry
 Directory
 NJ History
Quick Links
 Directory
 Job Search
 History
 Advertising
 
Learn vital information on HIV Testing.
 
Bone health resources at your fingertips.
 
Facilities
 

EquipNet Auction: Post Your Surplus Equipment Today for Immediate Global Exposure!

Looking for the right candidate? Try our free job posting trial


New Jersey Life Science Industry Directory

Silverback Therapeutics

Target your advertising by state, region or nationwide for the same low rate

Banner Advertising | Event Advertising

Celator Pharmaceuticals, Inc.


Celator Pharmaceuticals, Inc.
200 Princeton South Corporate Center Suite 180
Ewing, NJ 08628
 
 
Phone: (609) 243-0123
Fax: (609) 243-0202
Year Established:  2000
Ticker: CPXX
Exchange: NASDAQ
Main Contact: Derek Miller, CBO
 
Other Contacts:  Matthew Young, Executive VP & CFO
Karen Smith, M.D., Ph.D., M.B.A., CMO
Bruce C. Cozadd, Chairman & CEO
Craig C. Parker, Senior VP, Corporate Development
Michael P. Miller, Seniopr VP, US Commercial
Robert McKague, Senior VP & associate General Counsel
 
Company Description

Celator Pharmaceuticals, a subsidiary of Jazz Pharmaceuticals, is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®,the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:cisplatin), and CPX-8, a hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory.

On May 31, 2016, Jazz Pharmaceuticals and Celator Pharmaceuticals announced an agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in cash, or approximately $1.5 billion.



Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2019 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

NewJerseyLifeScience.com is owned and published by Info.Resource, Inc.